Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Instead, they are considering whether that patient's illness is, in fact, under control with Humira. If it's not, they are switching to drugs that use other mechanisms. This benefits Skyrizi and ...

Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

Crucially, Humira costs the NHS more than £500 million a year, a sum that NHS England wants to see fall through biosimilar use. Sandoz is one such company that hopes to offer the NHS savings ...